Pierre Fabre Medicament
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Pierre Fabre Medicament sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Pierre Fabre Medicament: 8 sponsored US clinical trials, 5 recruiting.
Pierre Fabre Medicament sponsors 8 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 2 completed. 1 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Allogeneic Hematopoietic Cell Transplant, with 2 trials.
Upper-quartile sponsor footprint
Pierre Fabre Medicament sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
NCT06669117
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
NCT06567015
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
NCT06043817
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
NCT04554914
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
NCT03394365
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
NCT04913285
Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer
NCT03693170
Brain Imaging Study of F17464
NCT01689038
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Pierre Fabre Medicament pipeline
5 recruiting of 8 indexed (63% open); 2 completed (25%).
Phase mix: 1 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Allogeneic Hematopoietic Cell Transplant (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Pierre Fabre Medicament: open-pipeline peers nationwide
Peers matched on 8 registered trials and 63% open enrollment, not the therapeutic-area sidebar.
Pierre Fabre Medicament sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 63% open enrollment (± trial volume)
- Canadian Cancer Trials Group · 63% recruiting · 16 trials
- CellSight Technologies · 63% recruiting · 8 trials
- Cook Children's Health Care System · 63% recruiting · 8 trials
- Nurix Therapeutics · 63% recruiting · 8 trials
Related
What to do with this Pierre Fabre Medicament page
8 registered trials is a research-attention snapshot, not an endorsement of Pierre Fabre Medicament or any single study.
- 5 of Pierre Fabre Medicament's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Allogeneic Hematopoietic Cell Transplant is the condition Pierre Fabre Medicament studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Allogeneic Hematopoietic Cell Transplant trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Pierre Fabre Medicament pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.